Vericel Corp (VCEL)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $2.05B
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Latest financial period: June 30, 2026
Filed with the SEC: July 30, 2026
Estimated earnings date: November 5, 2026
Profit #920 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 37.2% | 35.1% | 34.8% | 31.5% |
Growth #194 of 1484 companies
Payout #1117 of 1484 companies
Safety #248 of 1484 companies
Price #1144 of 1484 companies
